Status:
COMPLETED
Study of Nesiritide in Diastolic Heart Failure.
Lead Sponsor:
Massachusetts General Hospital
Collaborating Sponsors:
Scios, Inc.
Conditions:
Diastolic Heart Failure
Eligibility:
All Genders
18+ years
Phase:
PHASE1
PHASE2
Brief Summary
We hypothesize that nesiritide will have favorable effect in decreasing heart filling pressures and echocardiogram studies.
Detailed Description
In previous studies, patients with systolic heart failure were given nesiritide and had reduced heart filling pressures. The FDA has approved nesiritide for these patients. Between one-third and one-...
Eligibility Criteria
Inclusion
- Elevated heart filling pressure. Ejection fraction \>45%. Blood pressure \>90. Physician feels that the patient needs intravenous medication for heart failure.
- \-
Exclusion
- Patients receiving intravenous medication. Patients with significant heart disease or who are unstable. Patients with kidney failure or severe heart valve disease.
- \-
Key Trial Info
Start Date :
December 1 2002
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2003
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT00309868
Start Date
December 1 2002
End Date
December 1 2003
Last Update
March 26 2014
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.